Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia : a randomized trial
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response [PR], minimal response [MR]) were 44 of 56 (78.57%) in Arm A and 46 of 49 (93.88%) in Arm B at days 42 and 46, respectively (P = 0.0284). Total final responses (at day 180 from initial response) were 26 of 43 (60.47%) in Arm A and 23 of 39 (58.97%) in Arm B (P = 0.8907). Total persistent responses (at 12 months from initial response) were 25 of 31 (80.65%) in Arm A and 20 of 36 (55.56%) in Arm B (P = 0.0292). Seven relapses occurred. Median follow-up was 44.4 months. Overall survival was 100% at 48 months, overall disease-free survival was 81.11% at 48 months from day 180. PDN and pulsed HD-DXM were well tolerated; HD-DXM allows effective initial responses but less long lasting than PDN. This trial was registered at www.clinicaltrials.gov as #NCT00657410.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 6 vom: 26. März, Seite 1529-1540 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 29.03.2024 published: Print ClinicalTrials.gov: NCT00657410 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023010975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36721573X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36721573X | ||
| 003 | DE-627 | ||
| 005 | 20240330000802.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023010975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM36721573X | ||
| 035 | |a (NLM)38231017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mazzucconi, Maria Gabriella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia |b a randomized trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT00657410 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a ABSTRACT: A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response [PR], minimal response [MR]) were 44 of 56 (78.57%) in Arm A and 46 of 49 (93.88%) in Arm B at days 42 and 46, respectively (P = 0.0284). Total final responses (at day 180 from initial response) were 26 of 43 (60.47%) in Arm A and 23 of 39 (58.97%) in Arm B (P = 0.8907). Total persistent responses (at 12 months from initial response) were 25 of 31 (80.65%) in Arm A and 20 of 36 (55.56%) in Arm B (P = 0.0292). Seven relapses occurred. Median follow-up was 44.4 months. Overall survival was 100% at 48 months, overall disease-free survival was 81.11% at 48 months from day 180. PDN and pulsed HD-DXM were well tolerated; HD-DXM allows effective initial responses but less long lasting than PDN. This trial was registered at www.clinicaltrials.gov as #NCT00657410 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Rodeghiero, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Avvisati, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Gugliotta, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggeri, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Vianelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Fazi, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Paoloni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Sargentini, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Baldacci, Erminia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferretti, Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Vincelli, Iolanda Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Carli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Fortuna, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Di Ianni, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Ranalli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Palandri, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Polverelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Lugli, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Rivolti, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Patriarca, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Rago, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a D'Adda, Mariella |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Siragusa, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Sibilla, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Carella, Angelo Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Battistini, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Zaja, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchia, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Di Renzo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Crugnola, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Giuffrida, Anna Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Krampera, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Tafuri, Agostino |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 6 vom: 26. März, Seite 1529-1540 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:6 |g day:26 |g month:03 |g pages:1529-1540 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023010975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 6 |b 26 |c 03 |h 1529-1540 | ||